Summary
Eli Lilly and Company (LLY) filed an 8-K on November 29, 2006, reporting on decisions made regarding its European facilities. The most significant development is the approved plan to close the R&D facility in Mont St. Guibert, Belgium, by June 30, 2007. This closure is a result of the company's ongoing strategic review of its European operations, which was previously announced in June 2006. The company has finalized a social package, including severance payments, with the site's works council to manage the transition. Investors should note that this closure will result in significant restructuring charges, primarily impacting the fourth quarter of 2006. Eli Lilly anticipates total charges of approximately $100-110 million, with the majority attributed to severance payments and lease termination costs ($90-95 million), largely expected to be cash outlays. Additionally, non-cash asset impairment charges of $10-15 million are also projected. This event signifies a strategic move by Lilly to streamline its R&D infrastructure in Europe.
Key Highlights
- 1Eli Lilly's Board of Directors approved the closure of its R&D facility in Mont St. Guibert, Belgium.
- 2The facility closure is scheduled to be completed by June 30, 2007.
- 3A social package, including severance payments, has been agreed upon with the Mont St. Guibert works council.
- 4The company expects to incur restructuring charges of approximately $100-110 million related to this closure.
- 5The majority of these charges ($90-95 million) are for severance and lease termination costs, anticipated to be cash expenses.
- 6Non-cash asset impairment charges of $10-15 million are also expected.
- 7This decision is part of a broader review of European facilities initiated in June 2006.